Previous 10 | Next 10 |
180 Life Sciences (NASDAQ: ATNF) CEO Dr. James Woody issued a letter to stockholders of the clinical-stage biotechnology company that has its lead indication in phase 2b clinical trial and is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibro...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has closed its previously announced private placement of 2,500,000 shares of its common stock and accompa...
PALO ALTO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and ...
Gainers: Sonnet BioTherapeutics (NASDAQ:SONN) +127%. Sonoma Pharmaceuticals (NASDAQ:SNOA) +90%. DLocal (NASDAQ:DLO) +26%. Ensysce Biosciences (NASDAQ:ENSC) +23%. Macy's (NYSE:M) +22%. NLS Pharmaceutics (NASDAQ:NLSP) +21%. China Liberal Education (NASDAQ:CLEU) +19%. AudioEye (NASDAQ:AEYE) +14%...
Shares of 180 Life Sciences (NASDAQ: ATNF) , a clinical-stage drugmaker, are under pressure. Investors aren't happy because the company has announced the second dilutive capital raise since it completed a transaction with KBLM Merger Corp IV to gain its stock market listing last yea...
Gainers: Sonnet BioTherapeutics SONN +127%, Ensysce Biosciences (NASDAQ:ENSC) +71%, Sonoma Pharmaceuticals SNOA +65%, Petros Pharmaceuticals (NASDAQ:PTPI) +6%, Biocept (NASDAQ:BIOC) +5%. Losers: PharmaCyte Biotech PMCB -62%, Ontrak OTRK...
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional invest...
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today anno...
The following slide deck was published by 180 Life Sciences Corp. in conjunction with this event. For further details see: 180 Life Sciences (ATNF) Investor Presentation - Slideshow
180 Life Sciences (NASDAQ: ATNF) , a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that board chairman Jagdeep Nanchahal will be presenting the keynote address at the up...
News, Short Squeeze, Breakout and More Instantly...
180 Life Sciences Corp Com Company Name:
ATNF Stock Symbol:
NASDAQ Market:
180 Life Sciences Corp Com Website:
180 Life Sciences (NASDAQ: ATNF) today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “hearings panel”) of the Nasdaq Stock Market LLC that it has granted the company’s request for additional time to achieve compliance with Nasdaq’...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq S...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...